Themis Medicare Ltd. Launched Lenzetto ¡Global brand of Estradiol Novel Drug Delivery System for treatment of Menopausal symptoms" As life span of women is increasing in India, post-menopausal health status assumes increasing importance in Women's Healthcare. Most post-menopausal women remain unaware of the short and long-term implications of menopause due to lack of recognition of menopausal symptoms and unavailability of safe and convenient treatment options. Themis Medicare Ltd. (Themis), a Pharmaceutical company headquartered in Mumbai with a legacy of over 50 years of making new treatment options available, announced the launch of a novel transdermal Estradiol spray Lenzetto« in the Indian market for treatment of Menopausal Symptoms. Lenzetto« has a clinical experience in 40 countries and is approved by USFDA & EMA for the treatment of Menopausal Symptoms. Lenzetto is manufactured in Europe by Gedeon Richter, The Global Innovators in Women's Health.

Lenzetto« a novel transdermal estradiol with Metered Dose Transdermal Spray Technology) delivers therapeutic doses of estradiol to the skin, using a metering pump containing 1.53 mg/spray estradiol hemihydrate. Transdermal delivery of estrogen is well established in clinical practice and ensures sufficient serum estradiol levels to alleviate Menopausal Symptoms like hot flashes, night sweats etc. at lower overall estradiol exposure while avoiding some of the consequences of high hepatic exposure and first-pass metabolism.

Clinical studies have shown that estradiol delivered in Lenzetto« 1.53 mg/spray transdermal spray formulation is absorbed through the skin and provides steady serum concentrations throughout 24 hrs. for the treatment of menopausal symptoms in peri-menopausal and postmenopausal women. Various studies suggest that 1.53 mg estradiol transdermal spray is a valuable HRT option, demonstrating high acceptability and satisfaction amongst menopausal women, which enhances adherence to treatment.

Guidelines from various Menopause Societies around the world like British Menopause Society, International Menopause Society and North American Menopause Society recommend Transdermal as a preferred route for Estradiol for treatment of Menopausal Symptoms.